The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas.

摘要: In a significant fraction of patients with NHL or HD, disease develops that is resistant to conventional chemotherapy. Experience using high-dose chemotherapy, without TBI, and ABMR expanding. remissions can be achieved in approximately half the relapsed advanced disease. This may also true who do not respond regimens. High-dose chemoradiotherapy regimens are toxic require extensive supportive care. Relapse frequently occurs areas previous disease, suggesting failure conditioning regimen rather an infusion occult tumor cells autologous bone marrow had occurred. Thus, role purging this therapy needs further evaluated compared findings involving nonpurged reinfusion. It important evaluate effects more vigorous attempts at cytoreduction bulky prior ABMR. We recommend investigational setting used (1) HD experience relapse after MOPP/ABVD equivalent (2) intermediate high-grade whose recurs Potential for development include use modality as intensification following poor prognostic features. Toxicity decreased efficacy increased only if administered have been heavily pretreated lower burden good performance status. The chemotherapy nodular lymphomas known point. Finally, has definite salvaging malignant lymphomas. Many issues need resolved, including (i) optimal timing approach, (ii) regimen, (iii) past 10 years led gains. During next years, it possible refine find solutions above issues.